◀ Back to CDK2
CCNE1 — CDK2
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
CCNE1
→
CDK2
(increases, CCNE1 Activity)
Evidence: Three groups have reported that Cyclin E ubiquitinylation is mediated by the ubiquitin ligase SCFFbw7 The interaction between Fbw7 and Cyclin E is phosphorylation dependent since mutation on two residues phosphorylated by Cdk2 impairs Cyclin E ability to bind Fbw7. Furthermore, SCFFbw7 is able to ubiquitinylate Cyclin E in a phosphorylation-dependent manner in vitro.
-
OpenBEL Selventa BEL large corpus:
Complex of CCNE1-CDK2
→
CDKN1B
(decreases)
Evidence: In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways.
-
OpenBEL Selventa BEL large corpus:
Complex of CCNE1-CDK2
→
E2F1
(increases, CCNE1/CDK2 Activity)
Hartman et al., Oncogene 2004*
Evidence: Expression of HES-1 in T47D cells inhibited G(1)/S-phase transition and activation of Cdk2 elicited by estrogen.
-
OpenBEL Selventa BEL large corpus:
Complex of CCNE1-CDK2
→
HES1
(decreases, CCNE1/CDK2 Activity)
Hartman et al., Oncogene 2004*
Evidence: Expression of HES-1 in T47D cells inhibited G(1)/S-phase transition and activation of Cdk2 elicited by estrogen.
-
BioCarta cell cycle: g1/s check point:
RB/HDAC/ABL/E2F-1/DP-1 complex (E2F1-RB1-TFDP1-ABL1-HDAC1)
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, collaborate)
-
BioCarta cell cycle: g1/s check point:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
E2F-1/DP-1 complex (TFDP1-E2F1)
(modification, activates)
-
BioCarta e2f1 destruction pathway:
RB/E2F-1 complex (E2F1-RB1)
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, collaborate)
-
BioCarta e2f1 destruction pathway:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
E2F-1 (E2F1)
(modification, activates)
-
BioCarta influence of ras and rho proteins on g1 to s transition:
RhoA (RHOA)
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, activates)
-
BioCarta p53 signaling pathway:
RB/E2F-1 complex (E2F1-RB1)
→
CDK2/CYCLIN E/PCNA complex (CDK2-CCNE1-PCNA)
(modification, collaborate)
-
BioCarta p53 signaling pathway:
CDK2/CYCLIN E/PCNA complex (CDK2-CCNE1-PCNA)
→
p21 (CDKN1A)
(modification, activates)
-
BioCarta p53 signaling pathway:
CDK2/CYCLIN E/PCNA complex (CDK2-CCNE1-PCNA)
→
RB (RB1)
(modification, activates)
-
BioCarta cell cycle: g1/s check point:
CDC25A
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, activates)
-
BioCarta cell cycle: g1/s check point:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
p21 (CDKN1A)
(modification, activates)
-
BioCarta regulation of p27 phosphorylation during cell cycle progression:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
p27 (CDKN1B)
(modification, activates)
-
BioCarta cyclin e destruction pathway:
CDK2
→
Cyclin E (CCNE1)
(modification, activates)
-
BioCarta cdk regulation of dna replication:
Cyclin E/CDK2/p27 complex (CCNE1-CDK2-CDKN1B)
→
ORC/CDC6/CDT1/Cyclin E/CDK2/p27 complex (ORC1L-ORC2L-ORC3L-ORC4L-ORC5L-ORC6L-CDC6-CDT1-CCNE1-CDK2-CDKN1B)
(modification, collaborate)
-
BioCarta cdk regulation of dna replication:
Cyclin E/CDK2/p27 complex (CCNE1-CDK2-CDKN1B)
→
ORC/CDC6/CDT1 complex (ORC1L-ORC2L-ORC3L-ORC4L-ORC5L-ORC6L-CDC6-CDT1)
(modification, collaborate)
-
BioCarta cdk regulation of dna replication:
ORC/CDC6/CDT1/Cyclin E/CDK2/p27 complex (ORC1L-ORC2L-ORC3L-ORC4L-ORC5L-ORC6L-CDC6-CDT1-CCNE1-CDK2-CDKN1B)
→
ORC/CDC6/CDT1 complex (ORC1L-ORC2L-ORC3L-ORC4L-ORC5L-ORC6L-CDC6-CDT1)
(modification, collaborate)
-
BioCarta influence of ras and rho proteins on g1 to s transition:
RB/E2F-1 complex (E2F1-RB1)
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, collaborate)
-
BioCarta influence of ras and rho proteins on g1 to s transition:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
RB (RB1)
(modification, activates)
-
BioCarta cdk regulation of dna replication:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
Cyclin E/CDK2/p27 complex (CCNE1-CDK2-CDKN1B)
(modification, collaborate)
-
BioCarta cdk regulation of dna replication:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
p27 (CDKN1B)
(modification, collaborate)
-
BioCarta cdk regulation of dna replication:
Cyclin E/CDK2/p27 complex (CCNE1-CDK2-CDKN1B)
→
p27 (CDKN1B)
(modification, collaborate)
-
BioCarta cyclins and cell cycle regulation:
RB/E2F-1 complex (E2F1-RB1)
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, collaborate)
-
BioCarta cyclins and cell cycle regulation:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
RB (RB1)
(modification, activates)
-
BioCarta cdk regulation of dna replication:
ORC/CDC6/CDT1/Mcm2-7/SCF complex (ORC1L-ORC2L-ORC3L-ORC4L-ORC5L-ORC6L-CDC6-CDT1-MCM2-MCM3-MCM4-MCM5-MCM6-MCM7-KITLG)
→
ORC/CDC6/CDT1/Cyclin E/CDK2/p27 complex (ORC1L-ORC2L-ORC3L-ORC4L-ORC5L-ORC6L-CDC6-CDT1-CCNE1-CDK2-CDKN1B)
(regulation of DNA replication initiation, activates)
-
BioCarta regulation of p27 phosphorylation during cell cycle progression:
CDK2
→
Cyclin E/CDK2 complex (CCNE1-CDK2)
(modification, collaborate)
-
BioCarta regulation of p27 phosphorylation during cell cycle progression:
CDK2
→
Cyclin E (CCNE1)
(modification, collaborate)
-
BioCarta regulation of p27 phosphorylation during cell cycle progression:
Cyclin E/CDK2 complex (CCNE1-CDK2)
→
Cyclin E (CCNE1)
(modification, collaborate)
-
KEGG Cell cycle:
Complex of CCNE1-CCNE2-CDK2
→
CDKN1B/CDKN1C
(protein-protein, inhibition)
-
KEGG Cell cycle:
CDKN1A
→
Complex of CCNE1-CCNE2-CDK2
(protein-protein, inhibition)
-
KEGG Cell cycle:
Complex of CUL1-RBX1-SKP1-SKP2
→
Complex of CCNE1-CCNE2-CDK2
(protein-protein, inhibition)
-
KEGG Cell cycle:
Complex of CCNE1-CCNE2-CDK2
→
RB1
(protein-protein, inhibition)
-
KEGG Oocyte meiosis:
Complex of CCNE1-CCNE2-CDK2
→
ANAPC1/ANAPC10/ANAPC11/ANAPC13/ANAPC2/ANAPC4/ANAPC5/ANAPC7/CDC16/CDC23/CDC26/CDC27
(protein-protein, inhibition)
-
KEGG p53 signaling pathway:
CDKN1A
→
Complex of CCNE1-CCNE2-CDK2
(protein-protein, inhibition)
-
KEGG Pathways in cancer:
Complex of CCNE1-CCNE2-CDK2
→
RB1
(protein-protein, activation)
-
KEGG Pathways in cancer:
CDKN1B
→
Complex of CCNE1-CCNE2-CDK2
(protein-protein, inhibition)
-
KEGG Prostate cancer:
Complex of CCNE1-CCNE2-CDK2
→
RB1
(protein-protein, activation)
-
KEGG Prostate cancer:
CDKN1B
→
Complex of CCNE1-CCNE2-CDK2
(protein-protein, missing interaction)
-
KEGG Small cell lung cancer:
Complex of CCNE1-CCNE2-CDK2
→
RB1
(protein-protein, activation)
-
KEGG Small cell lung cancer:
CDKN1B
→
Complex of CCNE1-CCNE2-CDK2
(protein-protein, inhibition)
-
NCI Pathway Database FOXM1 transcription factor network:
RB1/FOXM1C complex (FOXM1-RB1)
→
Cyclin A-E1/CDK1-2 complex (CCNA2_CCNE1-CDK2)
(modification, collaborate)
Lüscher-Firzlaff et al., FEBS Lett 2006, Wierstra et al., Biochem Biophys Res Commun 2006, Wierstra et al., Biol Chem 2006
Evidence: mutant phenotype, assay, reporter gene, physical interaction
-
NCI Pathway Database BARD1 signaling events:
CDK2/Cyclin E1 complex (CDK2-CCNE1)
→
BRCA1/BARD1 complex (BRCA1-BARD1)
(modification, activates)
Hayami et al., Cancer Res 2005*
Evidence: assay, other species
-
NCI Pathway Database Regulation of retinoblastoma protein:
CDK2/Cyclin E1 complex (CDK2-CCNE1)
→
RB1 (RB1)
(modification, activates)
Harbour et al., Cell 1999, Chan et al., Nat Cell Biol 2001, Rubin et al., Cell 2005
Evidence: mutant phenotype, assay, reporter gene, physical interaction
-
NCI Pathway Database Regulation of retinoblastoma protein:
CDK2/Cyclin E1 complex (CDK2-CCNE1)
→
p21CIP1/CDK2 complex (CDKN1A-CDK2)
(modification, activates)
Harbour et al., Cell 1999, Chan et al., Nat Cell Biol 2001, Rubin et al., Cell 2005
Evidence: mutant phenotype, assay, reporter gene, physical interaction
-
NCI Pathway Database Regulation of retinoblastoma protein:
CDK2/Cyclin E1 complex (CDK2-CCNE1)
→
RB1/E2F1-3/DP complex (RB1-E2F3_E2F2_E2F1-TFDP1)
(modification, activates)
Harbour et al., Cell 1999, Chan et al., Nat Cell Biol 2001, Rubin et al., Cell 2005
Evidence: mutant phenotype, assay, reporter gene, physical interaction
-
NCI Pathway Database Signaling events mediated by PRL:
Cyclin A (CCNA2)
→
CDK2/Cyclin E1 complex (CDK2-CCNE1)
(G1/S transition of mitotic cell cycle, collaborate)
-
NCI Pathway Database mTOR signaling pathway:
mTORC1 complex (MTOR-MLST8-RPTOR)
→
CDK2/Cyclin E1 complex (CDK2-CCNE1)
(modification, activates)
Mayer et al., Genes Dev 2004
Evidence: mutant phenotype, assay
-
NCI Pathway Database mTOR signaling pathway:
CDK2/Cyclin E1 complex (CDK2-CCNE1)
→
TIFIA (RRN3)
(modification, activates)
Mayer et al., Genes Dev 2004
Evidence: mutant phenotype, assay
-
NCI Pathway Database Signaling events mediated by PRL:
p21CIP1 (CDKN1A)
→
CDK2/Cyclin E1 complex (CDK2-CCNE1)
(modification, activates)
-
Reactome Reaction:
CDK2
→
CCNE1
(direct_complex)
Aprelikova et al., J Biol Chem 1995, Desai et al., Mol Cell Biol 1995
-
Reactome Reaction:
CDK2
→
CCNE1
(reaction)
Desai et al., Mol Cell Biol 1995
-
WikiPathways G1 to S cell cycle control:
CDK2
→
CCNE1
(activation)
-
WikiPathways Human Thyroid Stimulating Hormone (TSH) signaling pathway:
CCNE1
→
CDK2
(activation)
-
WikiPathways Human Thyroid Stimulating Hormone (TSH) signaling pathway:
CDK2
→
CCNE1
(activation)
-
WikiPathways Retinoblastoma (RB) in Cancer:
CDKN1B
→
Complex of CDK2-CCNE1
(mim-inhibition)
-
WikiPathways Retinoblastoma (RB) in Cancer:
Complex of CDK2-CCNE1
→
RB1
(mim-inhibition)
-
WikiPathways Retinoblastoma (RB) in Cancer:
CDKN1A
→
Complex of CDK2-CCNE1
(mim-inhibition)
-
WikiPathways Retinoblastoma (RB) in Cancer:
MYC
→
Complex of CDK2-CCNE1
(mim-stimulation)
-
WikiPathways Signaling Pathways in Glioblastoma:
CDKN1B
→
Complex of CCNE1-CDK2
(mim-inhibition)
-
WikiPathways Signaling Pathways in Glioblastoma:
Complex of CCNE1-CDK2
→
RB1
(mim-inhibition)
-
WikiPathways miRNA Regulation of DNA Damage Response:
Complex of CDK4-CCND1-CDK6-CCND2-CCND3-CDK5
→
Complex of CDK2-CCNE2-CCNE1
(inhibition)
-
WikiPathways miRNA Regulation of DNA Damage Response:
CDKN1A
→
Complex of CDK2-CCNE2-CCNE1
(inhibition)
-
WikiPathways DNA Damage Response:
Complex of CDK4-CCND1-CDK6-CCND2-CCND3-CDK5
→
Complex of CDK2-CCNE2-CCNE1
(inhibition)
-
WikiPathways DNA Damage Response:
CDKN1A
→
Complex of CDK2-CCNE2-CCNE1
(inhibition)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Bind Interaction:
CCNE1
—
CDK2
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(x-ray crystallography)
Honda et al., EMBO J 2005*
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(coimmunoprecipitation)
He et al., Oncogene 2005*
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(coimmunoprecipitation)
Orend et al., Oncogene 1998
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(coimmunoprecipitation)
Laman et al., EMBO J 2005
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(coimmunoprecipitation)
Ji et al., Mol Cell 2004
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(coimmunoprecipitation)
Fang et al., Science 1996*
-
IRef Bind_translation Interaction:
CCNE1
—
CDK2
(coimmunoprecipitation)
Poon et al., J Biol Chem 1996
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Levkau et al., Mol Cell 1998*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
McKenzie et al., Cancer Res 2003*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Chu et al., Cell 2007*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(direct interaction, pull down)
Mayer et al., Genes Dev 2004
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Shanahan et al., Mol Cell Biol 1999
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(association, biochemical)
Koff et al., Science 1992*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Koff et al., Science 1992*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Connor et al., Mol Biol Cell 2003*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(direct interaction, pull down)
Boudrez et al., J Biol Chem 2000*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Larrea et al., Proc Natl Acad Sci U S A 2009*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Varshochi et al., J Biol Chem 2005*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Jeong et al., Mol Cancer Ther 2010*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Zhao et al., Genes Dev 1998*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Bustany et al., Cell Signal 2011*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Yeh et al., J Biol Chem 2006*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Hui et al., Circ Res 2011*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Baydoun et al., Molecular cancer 2010*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Datta et al., Cell Growth Differ 1998
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(direct interaction, pull down)
Manenti et al., Biochem J 1999*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Abbas et al., Cell cycle (Georgetown, Tex.) 2007*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Kiviharju-af Hällström et al., Proc Natl Acad Sci U S A 2007*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Kim et al., Anticancer Res 2007*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Harwell et al., J Biol Chem 2004*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Nishimura et al., Genes Cells 2005*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Matsumoto et al., Science 2004*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(colocalization, biochemical)
Kim et al., J Antibiot (Tokyo) 2000*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Peiretti et al., Eur J Cell Biol 2003*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Higashi et al., Eur J Biochem 1996
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Sheaff et al., Genes Dev 1997*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(direct interaction, pull down)
Higashi et al., Eur J Biochem 1996
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Musgrove et al., J Cell Biochem 1996*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Grim et al., J Cell Biol 2008*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Vlach et al., EMBO J 1996*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Liu et al., Cancer Lett 2009*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Ciarallo et al., Mol Cell Biol 2002*
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(direct interaction, pull down)
Desai et al., Mol Cell Biol 1995
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Poon et al., J Biol Chem 1996
-
IRef Biogrid Interaction:
CCNE1
—
CDK2
(physical association, affinity chromatography technology)
Varjosalo et al., Nat Methods 2013
-
MIPS CORUM p27-cyclinE-CDK2 complex:
p27-cyclinE-CDK2 complex complex (CCNE1-CDK2-CDKN1B)
Xu et al., J Biol Chem 2007
-
MIPS CORUM p27-cyclinE-Cdk2 - Ubiquitin E3 ligase (SKP1A, SKP2, CUL1, CKS1B, RBX1) complex:
p27-cyclinE-Cdk2 - Ubiquitin E3 ligase (SKP1A, SKP2, CUL1, CKS1B, RBX1) complex complex (CCNE1-CDK2-CDKN1B-CKS1B-CUL1-RBX1-SKP1-SKP2)
Xu et al., J Biol Chem 2007
-
MIPS CORUM CDK2-CCNE1 complex:
CDK2-CCNE1 complex complex (CCNE1-CDK2)
Fang et al., Science 1996*
-
IRef Corum Interaction:
Complex of RBX1-SKP1-CKS1B-CDKN1B-CDK2-CCNE1-SKP2-CUL1
(association, anti tag coimmunoprecipitation)
Xu et al., J Biol Chem 2007
-
IRef Corum Interaction:
CCNE1
—
CDK2
(association, coimmunoprecipitation)
Fang et al., Science 1996*
-
IRef Dip Interaction:
CCNE1
—
CDK2
(physical association, anti bait coimmunoprecipitation)
Larrea et al., Proc Natl Acad Sci U S A 2009*
-
IRef Hprd Interaction:
Complex of CDKN1A-CCNE1-CDK2-CDK2-CCNE1-CDKN1A-CCNE1-CDK2-CDKN1A
(in vivo)
Bao et al., FEBS Lett 2006*
-
IRef Hprd Interaction:
Complex of CDK2-CCNE1-ESR1-CDKN1A
(in vivo)
Maynadier et al., FASEB J 2008*
-
IRef Hprd Interaction:
Complex of 16 proteins
(in vivo)
Maynadier et al., FASEB J 2008*
-
IRef Hprd Interaction:
Complex of 19 proteins
(in vivo)
Lüscher-Firzlaff et al., FEBS Lett 2006
-
IRef Hprd Interaction:
Complex of 17 proteins
(in vivo)
Kashiwagi et al., Oncogene 2000*
-
IRef Hprd Interaction:
Complex of 19 proteins
(in vivo)
Cariou et al., Proc Natl Acad Sci U S A 2000*, Kossatz et al., EMBO J 2006*, Chu et al., Cell 2007*
-
IRef Hprd Interaction:
Complex of CDK2-PIN1-CCNE1-CCNE1-PIN1-CDK2-PIN1-CCNE1-CDK2
(in vivo)
Yeh et al., J Biol Chem 2006*
-
IRef Hprd Interaction:
Complex of 17 proteins
(in vivo)
Dhillon et al., Oncogene 2002
-
IRef Hprd Interaction:
Complex of CDK2-CDC5L-CCNE1-CDC5L-CDK2-CCNE1-CDC5L-CCNE1-CDK2
(in vivo)
Boudrez et al., J Biol Chem 2000*
-
IRef Hprd Interaction:
CCNE1
—
CDK2
(in vitro)
Koff et al., Science 1992*, Welcker et al., Mol Cell 2003*
-
IRef Hprd Interaction:
CCNE1
—
CDK2
(in vivo)
Koff et al., Science 1992*, Welcker et al., Mol Cell 2003*
-
IRef Hprd Interaction:
Complex of 33 proteins
(in vivo)
Dehde et al., Mol Cell Biol 2001
-
IRef Hprd Interaction:
Complex of UHRF2-CDK2-CCNE1-UHRF2-CCNE1-CDK2-UHRF2-CDK2-CCNE1
(in vivo)
Li et al., Biochem Biophys Res Commun 2004*
-
IRef Hprd Interaction:
Complex of CDK2-NPAT-CDK2-CCNE1-NPAT-CCNE1-CDK2-NPAT-CCNE1
(in vivo)
Zhao et al., Genes Dev 2000*, Zhao et al., Genes Dev 1998*
-
IRef Intact Interaction:
Complex of CCNE1-CDKN1A-CDK2
(association, pull down)
Chen et al., Mol Cell Biol 1996
-
IRef Intact Interaction:
Complex of 18 proteins
(association, tandem affinity purification)
Varjosalo et al., Cell reports 2013
-
IRef Intact Interaction:
Complex of 30 proteins
(association, tandem affinity purification)
Varjosalo et al., Nat Methods 2013
-
IRef Intact Interaction:
Complex of 22 proteins
(association, anti bait coimmunoprecipitation)
Chu et al., Cell 2007*
-
IRef Intact Interaction:
Complex of CCNE1-CDK2-PIN1
(association, anti tag coimmunoprecipitation)
Yeh et al., J Biol Chem 2006*
-
IRef Intact Interaction:
CCNE1
—
CDK2
(physical association, anti bait coimmunoprecipitation)
Zariwala et al., Oncogene 1998
-
IRef Intact Interaction:
CCNE1
—
CDK2
(direct interaction, inferred by curator)
Hermjakob et al., Nucleic Acids Res 2004
-
IRef Intact Interaction:
CCNE1
—
CDK2
(physical association, anti bait coimmunoprecipitation)
Felzien et al., Mol Cell Biol 1999*
-
IRef Intact Interaction:
CCNE1
—
CDK2
(physical association, anti tag coimmunoprecipitation)
Yeh et al., J Biol Chem 2006*
-
IRef Intact Interaction:
CCNE1
—
CDK2
(physical association, anti tag coimmunoprecipitation)
Baydoun et al., Molecular cancer 2010*
-
IRef Intact Interaction:
CCNE1
—
CDK2
(physical association, anti bait coimmunoprecipitation)
Chen et al., Mol Cell Biol 1996
-
IRef Intact Interaction:
CCNE1
—
CDK2
(physical association, pull down)
Chen et al., Mol Cell Biol 1996
-
IRef Intact Interaction:
Complex of CDK2-CCNE1
(association, pull down)
Yeh et al., J Biol Chem 2006*
-
IRef Ophid Interaction:
CCNE1
—
CDK2
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Li et al., Hum Pathol 2001
(Adenocarcinoma...) :
From the primary to the liver-metastatic foci,
cyclin E apparently decreased, and
CDK2 was
reduced almost to zero
Lüscher-Firzlaff et al., FEBS Lett 2006
:
Regulation of the transcription factor
FOXM1c by
Cyclin E/CDK2
Deb-Basu et al., Cell cycle (Georgetown, Tex.) 2006
:
MYC may
induce inappropriate DNA replication through the activation of
Cyclin E/CDK2 ... Hence, MYC appears induce inappropriate cell cycle transit, but not mitotic cellular division independent of
p27 mediated inhibition of
Cyclin E/Cdk2
Wierstra et al., Biochem Biophys Res Commun 2006
:
Cyclin E/Cdk2 activates
FOXM1c by releasing its transactivation domain from the repression by these two inhibitory domains
Chu et al., Cell 2007
(Breast Neoplasms...) :
Src phosphorylated p27 is shown to
inhibit cyclin
E-Cdk2 poorly in vitro, and Src transfection reduces
p27-cyclin E-Cdk2 complexes
Sukhanova et al., BMC developmental biology 2008
:
Our data demonstrate that
Cyclin E/Cdk2 kinase activity is absolutely required for S phase in SMW, and that
Dap is
required for the proper cell cycle arrest of cells exiting the SMW
Ghule et al., J Cell Physiol 2009
(Aneuploidy...) :
Transcription is controlled at the G1/S phase transition by the
Cyclin E/CDK2 mediated
induction of p220 ( NPAT )
/HiNF-P complexes at subnuclear domains designated Histone Locus Bodies ( HLBs ) that associate with histone gene clusters ... Transcription is controlled at the G1/S phase transition by the
Cyclin E/CDK2 mediated
induction of
p220 ( NPAT ) /HiNF-P complexes at subnuclear domains designated Histone Locus Bodies ( HLBs ) that associate with histone gene clusters
Zurlo et al., Mol Carcinog 2013
(Colonic Neoplasms...) :
Consistently, cyclin D1,
cyclin E , CDK2, and CDK4 proteins were reduced and histone H1-associated
CDK2 kinase activity
inhibited
Hartley et al., Dev Biol 1997
:
To investigate the function of cyclin E during the early cycles,
cyclin E/Cdk2 kinase activity was specifically
inhibited in fertilized eggs by a truncated form of the Xenopus
Cdk inhibitor, Xic1 ( Delta34Xic1 )